Clinical Trial: A Phase II Study to Evaluate the Efficacy and Safety of SKB571 in Recurrent or Metastatic HNSCC Participants

U.S., June 26 -- ClinicalTrials.gov registry received information related to the study (NCT07668154) titled 'A Phase II Study to Evaluate the Efficacy and Safety of SKB571 in Recurrent or Metastatic HNSCC Participants' on June 16.

Brief Summary: This is a multicenter, open-label, Phase II clinical study to assess the efficacy, safety, tolerability, PK characteristics, and immunogenicity of SKB571 in participants with recurrent or metastatic HNSCC.

Study Start Date: July 31

Study Type: INTERVENTIONAL

Condition: HNSCC

Intervention: DRUG: SKB571

SKB571

Recruitment Status: NOT_YET_RECRUITING

Sponsor: Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.

Disclaimer: Curated by HT Syndication....